Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax

Fineline Cube Jun 29, 2026
Company Deals

Abu Dhabi Health Department Partners with Sanofi to Establish Vaccine Innovation Center in HELM Cluster

Fineline Cube Jun 25, 2026
Company Deals

YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders

Fineline Cube Jun 24, 2026
Company Deals

Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital

Fineline Cube Jun 24, 2026
Company Deals

AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline

Fineline Cube Jun 24, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Eli Lilly’s Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use

Fineline Cube Jun 29, 2026
Company Drug

J&J’s TECVAYLI-Daratumumab Combo Receives CHMP Recommendation for Earlier Multiple Myeloma Treatment Line

Fineline Cube Jun 29, 2026
Company Deals

Hemay Pharma Completes Series D Financing for Autoimmune and Oncology Drugs

Fineline Cube Feb 9, 2023

China-based Ganzhou Hemay Pharmaceutical Co., Ltd, an innovative drug developer focused on autoimmune diseases and...

Company Deals

Neurodawn Completes Series A+ Financing for CNS Drug Development

Fineline Cube Feb 9, 2023

Neurodawn Pharmaceutical Co., Ltd, a central nervous system (CNS) drug developer based in Nanjing, has...

Company Drug

Grand Pharma Completes Patient Enrollment for STC3141 Sepsis Study

Fineline Cube Feb 9, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that all patients have completed enrollment...

Company Deals

Eyebright Medical Gains SIX Swiss Exchange Approval for GDR Offering

Fineline Cube Feb 9, 2023

Beijing-based ophthalmic device maker Eyebright Medical Technology Co., Ltd (SHA: 688050) has announced receiving conditional...

Company Deals

Teddy Clinical Research Lab Partners with Cerba Research for Global Services

Fineline Cube Feb 9, 2023

China-based Teddy Clinical Research Laboratory Limited, a joint venture (JV) between Dian Diagnostics (SHE: 300244)...

Company Deals

Junshi Biosciences’ COVID-19 Therapy Faces Supply Issues, Partners with Sihuan Pharma

Fineline Cube Feb 8, 2023

Junshi Biosciences’ (HKG: 1877, SHA: 688180) COVID-19 therapy JT001 (VV116) appears to be facing supply...

Company Deals

Macrolux Secures Series A Funding for Endoscopy Solutions

Fineline Cube Feb 8, 2023

Macrolux, an endoscopy intervention solutions provider based in Shenzhen, has reportedly raised close to RMB...

Company Deals

Hua Medicine Receives Milestone Payment from Bayer for Dorzagliatin

Fineline Cube Feb 8, 2023

China-based Hua Medicine has announced receiving a RMB 400 million (USD 59 million) milestone payment...

Company Drug

SciClone Pharmaceuticals Files for Hong Kong Market Approval of Danyelza

Fineline Cube Feb 8, 2023

SciClone Pharmaceuticals Inc. (Nasdaq: SCLN), which became a China-based company after going private in 2017,...

Company Deals

Asia Regenerative Medicine Raises Pre-Series A+ Funding for Bioartificial Organs

Fineline Cube Feb 8, 2023

Shenzhen-based Asia Regenerative Medicine (ARM) has reportedly raised “tens of millions” of renminbi in a...

Company Deals

Beijing Smart Beam Raises Series A+ Funding for CT X-Ray Tube Development

Fineline Cube Feb 8, 2023

Beijing Smart Beam Technology, a leading vacuum electronic device maker, has reportedly raised “tens of...

Company Deals

Asieris Partners with ReviR Therapeutics for Urogenital Cancer Research

Fineline Cube Feb 8, 2023

China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has struck a...

Company

Siemens Healthineers Reports Q1 Revenue Drop Amid COVID-19 Impact

Fineline Cube Feb 7, 2023

Germany-based medical device giant Siemens Healthineers AG has released its fiscal year 2023 Q1 financial...

Company

Astellas Pharma Reports Strong Q3 Results with 17.3% Revenue Growth

Fineline Cube Feb 7, 2023

Japan-based Astellas Pharma Inc. (TYO: 4503) has released its financial report for Q3 of its...

Company Drug

Fujian Cosunter’s HBV Therapy GST-HG141 Begins Phase II Trial

Fineline Cube Feb 7, 2023

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced the first patient enrollment and...

Company Drug

Harbour BioMed’s Anti-CCR8 Monoclonal Antibody HBM1022 Receives FDA IND Approval

Fineline Cube Feb 7, 2023

Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China,...

Company Drug

Eli Lilly’s Tirzepatide Achieves Primary Endpoints in Chinese Obesity Study

Fineline Cube Feb 7, 2023

US major Eli Lilly (NYSE: LLY) has announced that the Phase III SURMOUNT-CN study for...

Company Deals

Lifetech Partners with Jenscare for Structural Heart Disease Devices

Fineline Cube Feb 7, 2023

China-based Lifetech Scientific Corporation (HKG: 1302) has announced a partnership agreement with compatriot firm Jenscare...

Company Drug

Gracell’s CAR-T Therapy GC012F Receives FDA IND Approval

Fineline Cube Feb 7, 2023

Shanghai-based biotech Gracell Biotechnologies has reported receiving Investigational New Drug (IND) approval from the US...

Company

Gilead Sciences Reports Q4 and Full-Year 2022 Financial Results

Fineline Cube Feb 6, 2023

US major Gilead Sciences, Inc. (NASDAQ: GILD) last week reported Q4 and full-year 2022 financial...

Posts pagination

1 … 587 588 589 … 688

Recent updates

  • Eli Lilly’s Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use
  • Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax
  • J&J’s TECVAYLI-Daratumumab Combo Receives CHMP Recommendation for Earlier Multiple Myeloma Treatment Line
  • China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs
  • NHSA Advances Record 674 Drugs in 2026 Insurance Catalog Review with 92% Preliminary Pass Rate
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Eli Lilly’s Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use

Company Deals

Fosun Pharmaceutical Approves Hong Kong IPO Spin-Off of Vaccine Subsidiary Fosun Adgenvax

Company Drug

J&J’s TECVAYLI-Daratumumab Combo Receives CHMP Recommendation for Earlier Multiple Myeloma Treatment Line

Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.